Delivery Order SPE2DB24D1007-SPE2DB25FB5TH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count packaging) with a ceiling value of $7,756.44. This competitively awarded, firm fixed-price delivery order is not associated with any set-aside program and is scheduled for ultimate completion by August 7, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets per package. This is a firm fixed-price delivery order with a ceiling value of $1,315.41, with an ultimate completion date of July 23, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units) valued at $1,605.86. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 20, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a routine pharmaceutical supply transaction...
- The Defense Logistics Agency (DLA) awarded a $5,346.26 delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order, indicating it is issued under a larger indefinite delivery contract (IDC) vehicle. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $4,022.60. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is expected to reach completion by September 9, 2025. The delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion prime vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets, with a ceiling value of $67,208.92. This non-set-aside, competitively awarded contract employs firm fixed pricing and maintains an ultimate completion date of August 18, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package. This order is valued at $1,825.56 with a firm fixed price structure and carries a completion date of July 30, 2025. The contract involves no set-aside designation, indicating it was competitively awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $1,036.29. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dapagliflozin 5 mg tablets (30-count) on August 28, 2025, with a ceiling value of $1,296.48 and an ultimate completion date of August 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FB5THDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dapagliflozin 10 mg tablets in a 30-count package, with a ceiling value of $1,376.58. This competitively awarded, firm fixed-price contract was issued on September 26, 2025, with an ultimate completion date of September 29, 2025. The delivery order carries no set-aside designation, indicating it was competed among all eligible vendors. AmerisourceBergen Drug Corp will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with the DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime vendor on this comprehensive pharmaceutical support vehicle, the company supplies a broad range of medications, vaccines, and medical supplies to support military healthcare programs globally. The Dapagliflozin order represents a typical transaction within the company's extensive federal pharmaceutical distribution portfolio, supporting diabetes management across Defense Health Agency and other military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 9/26/25 |